Literature DB >> 31719050

Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.

Jashodeep Datta1,2, J Joshua Smith1,3, Walid K Chatila3,4, John C McAuliffe5,6, Cyriac Kandoth4, Efsevia Vakiani7, Timothy L Frankel5,8, Karuna Ganesh3,9, Isaac Wasserman5, Marla Lipsyc-Sharf9, Jose Guillem5, Garrett M Nash5, Philip B Paty5, Martin R Weiser5, Leonard B Saltz9, Michael F Berger3,4,7, William R Jarnagin5, Vinod Balachandran5, T Peter Kingham5, Nancy E Kemeny9, Andrea Cercek9, Julio Garcia-Aguilar5, Barry S Taylor3,4,10, Agnes Viale4, Rona Yaeger9, David B Solit3,4,9, Nikolaus Schultz3,4,10, Michael I D'Angelica1.   

Abstract

PURPOSE: We aimed to investigate genomic correlates underlying extremes of survivorship in metastatic colorectal cancer and their applicability in informing survival in distinct subsets of patients with metastatic colorectal cancer. EXPERIMENTAL
DESIGN: We examined differences in oncogenic somatic alterations between metastatic colorectal cancer cohorts demonstrating extremes of survivorship following complete metastasectomy: ≤2-year (n = 17) and ≥10-year (n = 18) survivors. Relevant genomic findings, and their association with overall survival (OS), were validated in two independent datasets of 935 stage IV and 443 resected stage I-IV patients.
RESULTS: In the extremes-of-survivorship cohort, significant co-occurrence of KRAS hotspot mutations and TP53 alterations was observed in ≤2-year survivors (P < 0.001). When validating these findings in the independent cohort of 935 stage IV patients, incorporation of the cumulative effect of any oncogenic Ras/B-raf (i.e., either KRAS, NRAS, or BRAF) and TP53 alteration generated three prognostic clusters: (i) TP53-altered alone (median OS, 132 months); (ii) Ras/B-raf-altered alone (65 months) or Ras/B-raf- and TP53 pan-wild-type (60 months); and (iii) coaltered Ras/B-raf-TP53 (40 months; P < 0.0001). Coaltered Ras/B-raf-TP53 was independently associated with mortality (HR, 2.47; 95% confidence interval, 1.91-3.21; P < 0.001). This molecular profile predicted survival in the second independent cohort of 443 resected stage I-IV patients. Coaltered Ras/B-raf-TP53 was associated with worse OS in patients with liver (n = 490) and lung (n = 172) but not peritoneal surface (n = 149) metastases. Moreover, coaltered Ras/B-raf-TP53 tumors were significantly more likely to involve extrahepatic metastatic sites with limited salvage options.
CONCLUSIONS: Genomic analysis of extremes of survivorship following colorectal cancer metastasectomy identifies a prognostic role for coaltered Ras/B-raf-TP53 and its association with distinct patterns of colorectal cancer metastasis. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31719050      PMCID: PMC7056517          DOI: 10.1158/1078-0432.CCR-19-2390

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Authors:  Georgios Antonios Margonis; Stefan Buettner; Nikolaos Andreatos; Yuhree Kim; Doris Wagner; Kazunari Sasaki; Andrea Beer; Christoph Schwarz; Inger Marie Løes; Maria Smolle; Carsten Kamphues; Jin He; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Per Eystein Lønning; John L Cameron; Richard A Burkhart; Armin Gerger; Federico N Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

2.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

3.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

4.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

5.  Colorectal cancer statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-03-01       Impact factor: 508.702

6.  P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.

Authors:  Koert P de Jong; Annette S H Gouw; Paul M J G Peeters; Marian Bulthuis; Lorian Menkema; Robert J Porte; Maarten J H Slooff; Harry van Goor; Anke van den Berg
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

7.  Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.

Authors:  W S Samowitz; K Curtin; K N Ma; D Schaffer; L W Coleman; M Leppert; M L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-09       Impact factor: 4.254

8.  Weighted false discovery rate controlling procedures for clinical trials.

Authors:  Yoav Benjamini; Rami Cohen
Journal:  Biostatistics       Date:  2016-07-21       Impact factor: 5.899

9.  Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.

Authors:  Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2019-05       Impact factor: 12.969

10.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.

Authors:  Beifang Niu; Kai Ye; Qunyuan Zhang; Charles Lu; Mingchao Xie; Michael D McLellan; Michael C Wendl; Li Ding
Journal:  Bioinformatics       Date:  2013-12-25       Impact factor: 6.937

View more
  23 in total

Review 1.  Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.

Authors:  Christin Lund-Andersen; Annette Torgunrud; Karianne Giller Fleten; Kjersti Flatmark
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Statistical Inference for High-Dimensional Pathway Analysis with Multiple Responses.

Authors:  Yang Liu; Wei Sun; Li Hsu; Qianchuan He
Journal:  Comput Stat Data Anal       Date:  2022-01-13       Impact factor: 1.681

3.  Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.

Authors:  Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-27       Impact factor: 4.339

4.  Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.

Authors:  Jashodeep Datta; Anna Bianchi; Iago De Castro Silva; Nilesh U Deshpande; Long Long Cao; Siddharth Mehra; Samara Singh; Christine Rafie; Xiaodian Sun; Xi Chen; Xizi Dai; Antonio Colaprico; Prateek Sharma; Austin R Dosch; Asha Pillai; Peter J Hosein; Nagaraj S Nagathihalli; Krishna V Komanduri; Julie M Wilson; Yuguang Ban; Nipun B Merchant
Journal:  Oncogene       Date:  2022-06-14       Impact factor: 8.756

5.  Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.

Authors:  Jashodeep Datta; Raja R Narayan; Debra A Goldman; Walid K Chatila; Mithat Gonen; James Strong; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; William R Jarnagin; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica
Journal:  Ann Surg       Date:  2020-11-17       Impact factor: 13.787

6.  KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer.

Authors:  Seo-Hyun Choi; Jin K Kim; Chin-Tung Chen; Chao Wu; Michael R Marco; Francisco M Barriga; Kevin O'Rourke; Raphael Pelossof; Xuan Qu; Qing Chang; Elisa de Stanchina; Jinru Shia; J Joshua Smith; Francisco Sanchez-Vega; Julio Garcia-Aguilar
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

7.  Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases.

Authors:  Lily V Saadat; Thomas Boerner; Debra A Goldman; Mithat Gonen; Timothy L Frankel; Efsevia Vakiani; T Peter Kingham; William R Jarnagin; Alice C Wei; Kevin C Soares; David B Solit; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2020-07-18       Impact factor: 5.344

8.  Association of genomic profiles and survival in early onset and screening-age colorectal cancer patients with liver metastases resected over 15 years.

Authors:  Raja R Narayan; Victoria G Aveson; Joanne F Chou; Henry S Walch; Francisco Sanchez-Vega; Gustavo Dos Santos Fernandes; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; Andrea Cercek; Mithat Gönen; Nikolaus Schultz; T Peter Kingham
Journal:  J Surg Oncol       Date:  2022-01-23       Impact factor: 2.885

Review 9.  Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer.

Authors:  Thomas M Diehl; Daniel E Abbott
Journal:  Curr Treat Options Oncol       Date:  2021-07-05

10.  Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer.

Authors:  Jung Yoon Choi; Sunho Choi; Minhyeok Lee; Young Soo Park; Jae Sook Sung; Won Jin Chang; Ju Won Kim; Yoon Ji Choi; Jin Kim; Dong-Sik Kim; Sung-Ho Lee; Junhee Seok; Kyong Hwa Park; Seon Hahn Kim; Yeul Hong Kim
Journal:  Cancer Res Treat       Date:  2020-02-16       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.